What were the five biggest stories of the week? Here’s what visitors to this site were reading. 5) Australian government, Hanwha sign IFV contract The federal government has signed contracts with Hanwha Defense Australia for 129 locally built Redback infantry fighting vehicles, to be built in Geelong for the Australian Army. Hanwha was announced as…
By Brent Balinski Nobody is exactly keen on getting a needle, and getting rid of them is an old idea. Some articles trace an alternative, microarray patches, back to the 1970s, but today we still generally get our vaccines and various other drugs the old way – jabbed into our muscles. Ideas are easy, but…
Needle free vaccine delivery company Vaxxas‘s skin patch system is an attractive alternative to vaccine delivery via injection, according to a new study. Published in the journal Vaccine, the study said the company’s high-density microarray patch (HD-MAP) (pictured) was particularly attractive in a pandemic. Its’ use would alleviate the strain on healthcare systems by enabling…
Needle-free vaccine delivery company Vaxxas has announced it was awarded $5.4 million from charitable foundation Wellcome for initial studies and a Phase I clinical trial of a potential second-generation typhoid vaccine delivered using Vaxxas’ technology. In a statement on Thursday, the Brisbane-based clinical-stage company said the project is expected to be completed within two years,…
Public hearings for the inquiry on developing advanced manufacturing in Australia will be held on Tuesday at 9:00 am in Brisbane, examining the health, robotics and space sectors. According to a statement on Monday, the House Standing Committee on Industry, Science and Resources will hear from stakeholders representing those sectors on “what is needed to…
Biotechnology company Vaxxas in partnership with the Queensland Government, has announced the opening of its global headquarters and state-of-the-art manufacturing facility in Brisbane. The company, which is commercialising a needle-free vaccine patch platform, has opened its custom-built 5,500m² Vaxxas Biomedical Facility to support the scale-up of Vaxxas’ needle-free vaccine technology platform. The company’s high-density microarray…
